Friday, September 04, 2020 9:34:28 AM
Elisabeth,
(Please forward to your Legal Team as well)...
The Appeals Judges asked Jonathan Singer to provide something they could use relative to the Novo case.
He tried very hard. No one argues that...
I read the Novo closing comments from the Novo Appeals Judge and I think we missed a chance on Wednesday that Jonathan tried to drive home to them (the bad Mori evidence.)
Below I pointed out to a friend where Jonathan may have been able to open a door for the Appeals Judges to grab onto…
(Not sure if it may weigh in the upcoming appeal to the Appeals Court.)
I am sure Jonathan is NOT HAPPY that they ignored the Mori problem (which is what Du primarily based her decision on) yet if you read below, maybe there is still a slim chance of getting Mori reviewed by pointing out what we all know to be the "red herring" in our loss (Mori)…
Please note that I am NOT an Attorney yet did take 2 or 3 Law classes at Drexel University and enjoyed them very much...
My comments to a friend:
There is a potential path that was mentioned in Novo's closing Summary by the Appealant Judge that said and/or implied had "bad" evidence been used that was intentionally compromised or used in favor of good evidence to bolster the Defendants case, a "But/For" review could have occurred.
Novo's Attorneys pointed out a problem with evidence that they felt compromised the Trial.
IN NOVO, THE JUDGES REVIEWED THE BAD EVIDENCE AND IMPLIED BAD EVIDENCE COULD HAVE CHANGED THE OUTCOME OF THE CASE..
In Novo: The Judge said in closing that the issue with the "bad" evidence (pointed out by Novo in their Appeal) was not enough to change the Obviousness determination YET it certainly would have in ours! Had Jonathan noted this and expressed it when asked how our case mirrored or did not mirror Novo, he could have said it was very similar (they knew it was) YET "BUT/FOR" the bad evidence introduced by the Defendants, this case would have had a different outcome as discussed in the Novo closing summary.
This potentially would have given our Judges something to grab on to (a pathway) seeing it was allowed and/or discussed in Novo.
(Dyke or Reyes said: There are cases already out there that we have to follow such as Novo. They wanted something to grasp.)
I know Jonathan hoped they would review Mori with (probably) the understanding that the Judges did not have to or maybe aren't allowed to review evidence in an Appeals case - yet the Summary in Novo apparently allows it... And his main point was "the bad evidence" effected the "weighing of the secondary considerations"...
I and everyone else heard him loud and clear!
(Maybe Amarin can use this in their upcoming appeal...)
THIS IS A "COPY and PASTE" RIGHT FROM THE NOVO APPEALS' CLOSING COMMENTS BY THE JUDGE:
START:
"Dr. Sturis was accused of failing to notify the PTO that the original test plan did not include his data calculations at 120 minutes. The Federal Circuit found it to be a nonmaterial omission because it did not qualify as “but-for” material. The Court explained that this was not a case in which adverse results were hidden in favor of more positive data, nor did the omission undermine the opinion stated in the declaration."
END
In our case the "cropped document showing Adverse Results" certainly undermined our case!
I apologize if my interpretation of any or all of this is off-base yet it doesn't appear so...
Hope this helps!
Recent AMRN News
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 10:31:04 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM